Skip to main content
    Q

    Quidel Corporation (QDEL)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $13.91
    +0.04 (+0.29%)

    Market Cap: $966.91M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    77%(30/39)
    Avg Surprise
    +52.86%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.18
    Range$0.18 - $0.18
    1 analysts
    EPS Revisions
    1
    0
    7d
    No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.85-79.0%
    60d ago$0.85-79.0%
    30d ago$0.93-80.8%
    7d ago$0.21-14.4%
    Current$0.18
    Revenue Consensus
    $628M
    Range$616M - $635M
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.22
    Range$0.20 - $0.25
    2 analysts
    Revenue Consensus
    $638M
    Range$615M - $651M
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.22---
    Sep 26EST
    		-$0.18---
    Jun 26
    Reported Aug 6
    		$0.13$-0.04+425.00%Beat+8.3%
    Mar 26
    Reported May 5
    		$-0.04N/A-111.11%Miss-105.4%
    Dec 25
    Reported Feb 11
    		$0.46$0.42+9.52%Beat-27.0%
    Sep 25
    Reported Nov 5
    		$0.80$0.51+56.86%Beat-5.9%
    Jun 25
    Reported Aug 5
    		$0.12$0.01+1100.00%Beat+271.4%
    Mar 25
    Reported May 7
    		$0.74$0.59+25.42%Beat+68.2%
    Dec 24
    Reported Feb 12
    		$0.63$0.58+8.62%Beat-46.2%
    Sep 24
    Reported Nov 7
    		$0.85$0.32+165.63%Beat-5.6%
    Jun 24
    Reported Jul 31
    		$-0.07N/A+70.83%Beat-126.9%
    Mar 24
    Reported May 8
    		$0.44$0.40+10.00%Beat-75.6%
    Dec 23
    Reported Feb 13
    		$1.17$2.06-43.20%Miss-33.5%
    Sep 23
    Reported Nov 1
    		$0.90$0.56+60.71%Beat-51.4%
    Jun 23
    Reported Aug 8
    		$0.26$0.26+0.00%Beat-88.9%
    Mar 23
    Reported May 3
    		$1.80$1.43+25.87%Beat-84.6%
    Dec 22
    Reported Feb 15
    		$1.76$1.42+23.94%Beat-75.9%
    Sep 22
    Reported Nov 2
    		$1.85$0.69+168.12%Beat-65.5%
    Jun 22
    Reported Aug 4
    		$2.34$2.68-12.69%Miss+212.0%
    Mar 22
    Reported May 4
    		$11.66$9.43+23.65%Beat+166.2%
    Dec 21
    Reported Feb 17
    		$7.29$5.61+29.95%Beat-34.1%
    Sep 21
    Reported Nov 4
    		$5.36$2.30+133.04%Beat-7.3%
    Jun 21
    Reported Aug 5
    		$0.75$1.19-36.97%Miss-59.7%
    Mar 21
    Reported May 6
    		$4.38$4.68-6.41%Miss+259.0%
    Dec 20
    Reported Feb 18
    		$11.07$10.10+9.60%Beat+1007.0%
    Sep 20
    Reported Oct 29
    		$5.78$4.70+22.98%Beat+725.7%
    Jun 20
    Reported Jul 30
    		$1.86$1.09+70.64%Beat+416.7%
    Mar 20
    Reported May 6
    		$1.22$0.95+28.42%Beat+34.1%
    Dec 19
    Reported Feb 12
    		$1.00$0.82+21.95%Beat+25.0%
    Sep 19
    Reported Oct 30
    		$0.70$0.64+9.38%Beat+18.6%
    Jun 19
    Reported Aug 8
    		$0.36$0.37-2.70%Miss+0.0%
    Mar 19
    Reported May 8
    		$0.91$1.05-13.33%Miss-29.5%
    Dec 18
    Reported Feb 13
    		$0.80$0.63+26.98%Beat+247.8%
    Sep 18
    Reported Nov 6
    		$0.59$0.49+20.41%Beat+227.8%
    Jun 18
    Reported Aug 7
    		$0.36$0.27+33.33%Beat+400.0%
    Mar 18
    Reported May 8
    		$1.29$0.98+31.63%Beat+186.7%
    Dec 17
    Reported Feb 21
    		$0.23$0.20+15.00%Beat+483.3%
    Sep 17
    Reported Nov 1
    		$0.18$0.13+38.46%Beat-
    Jun 17
    Reported Jul 26
    		$-0.12$-0.09-33.33%Miss-
    Mar 17
    Reported Apr 24
    		$0.45$0.29+55.17%Beat-
    Dec 16
    Reported Feb 8
    		$-0.06$0.02-400.00%Miss-

    Key Metrics

    Valuation
    P/E Ratio10.30EV/EBITDAN/A
    Price/FCF-4.50xFCF Yield-22.23%
    Profitability
    Profit Margin-39.20%Operating Margin-2.09%
    ROE-45.90%ROIC-17.93%
    Financial Health
    Debt/Equity1.63xInterest Coverage0.84x
    Current Ratio1.39xQuick Ratio0.76x
    Trading Statistics
    Beta0.78Avg Volume2.03M
    52-Week High$35.5852-Week Low$9.92

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$12.88
    SMA 20$11.77
    SMA 50$12.91
    SMA 200$17.26
    EMA 10$13.00
    EMA 20$12.52
    EMA 50$12.98
    EMA 200$16.76

    MACD

    Line: 0.31Signal: -0.13Hist: 0.44

    ADX

    ADX: 30.5+DI: 31.2-DI: 14.4

    Aroon & PSAR

    Aroon Up96.0
    Aroon Down60.0
    PSAR$11.39

    Bollinger Bands

    Upper Band$14.46
    Lower Band$9.09
    %B Position4562%(Upper)
    Band Width0.90

    RSI (14-Day)

    Neutral
    63.2

    Momentum Oscillators

    Stoch %K85.6
    Stoch %D88.1
    Williams %R-15.7
    ROC (10d)34.0%
    Momentum3.53
    CCI (20d)126.1
    MFI (14d)72.6

    Volatility Measures

    ATR (14d)$0.84(6.1%)
    StdDev (20d)1.34
    Hist Vol68.5%(High)

    Volume Flow

    VWAP$13.90
    OBV-28.2M
    AD Line-7.7M
    CMF (20d)0.157

    Volume Metrics

    Avg Vol (20d)2.1M
    Vol Ratio1.0x
    VWMA (20d)$12.08

    Pivot Points

    R3$15.48
    R2$15.06
    R1$14.47
    Pivot Point$14.05
    S1$13.46
    S2$13.04
    S3$12.45

    Advanced Oscillators

    TSI10.12
    Ultimate Osc59.4
    KST16.51

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$630.90M$619.80M$723.60M$699.90M$613.90M$692.80M$707.80M$727.10M$637.00M$711.00M$742.60M$744.00M
    Cost of Revenue$358.00M$356.00M$403.20M$364.30M$339.00M$349.50M$381.70M$374.80M$361.00M$378.90M$361.30M$374.60M
    Gross Profit$272.90M$263.80M$320.40M$335.60M$274.90M$343.30M$326.10M$352.30M$276.00M$332.10M$381.30M$369.40M
    Operating Expenses$294.70M$291.20M$386.70M$1.04B$455.60M$310.70M$426.50M$337.30M$393.50M$2.09B$341.20M$343.10M
    R&D$48.70M$44.90M$45.80M$41.50M$45.70M$53.20M$47.30M$55.90M$56.30M$59.20M$59.30M$61.50M
    SG&A$189.70M$199.30M$194.40M$186.90M$178.00M$187.00M$181.30M$186.40M$172.50M$204.70M$172.50M$194.10M
    Operating Income$-21,800,000$-27,400,000$-66,300,000$-704,800,000$-180,700,000$32.60M$-100,400,000$15.00M$-117,500,000$-1,758,000,000$40.10M$26.30M
    Interest Income$500,000$900,000$500,000$500,000$600,000$600,000$800,000$400,000$500,000$900,000$1.40M$1.30M
    Interest Expense$54.70M$51.10M$43.10M$46.10M$46.10M$42.30M$44.70M$49.50M$47.80M$31.80M$46.20M$29.20M
    Income Before Tax$-81,200,000$-79,500,000$-112,400,000$-756,900,000$-229,600,000$-8,800,000$-140,900,000$-28,800,000$-162,900,000$-1,798,900,000$-9,200,000$-15,500,000
    Income Tax Expense$11.70M$12.30M$18.30M$-23,900,000$25.80M$3.90M$37.50M$-8,900,000$-15,200,000$-92,900,000$-16,200,000$-2,800,000
    Net Income$-92,900,000$-91,800,000$-130,700,000$-733,000,000$-255,400,000$-12,700,000$-178,400,000$-19,900,000$-147,700,000$-1,706,000,000$7.00M$-12,700,000
    EBITDA$90.20M$81.40M$43.20M$-597,000,000$-76,400,000$140.60M$13.10M$133.80M$1.00M$-1,637,700,000$152.40M$144.20M
    EBIT$-26,500,000$-31,500,000$-69,300,000$-709,100,000$-186,700,000$33.50M$-96,200,000$20.70M$-115,100,000$-1,752,600,000$37.00M$31.10M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about QDEL

    Government Contracts

    Gov Obligations (TTM)
    $0
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    3
    New Awards (TTM)
    0
    Avg Remaining Term
    N/A

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    QuidelOrtho Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    QuidelOrtho Corporation announced the grant of equity awards to two new non-executive employees, consisting of restricted stock units (RSUs) for 50,323 shares of common stock. These "Inducement Grants" were approved by...

    StreetInsider•10/15/26•Neutral

    J.P. Morgan keeps USD 12.00 target for QuidelOrtho stock, 13.92 percent below price

    J.P. Morgan analyst Casey Woodring maintained a Sell rating on QuidelOrtho stock, setting a USD 12.00 price target...

    ad-hoc-news.de•10/15/26•Somewhat-Bearish

    QuidelOrtho Reports Q2 2026 Results: Full Earnings Call Transcript

    QuidelOrtho reported a 2% increase in total revenue for Q2 2026, with a 6% growth excluding China, and a 21% increase in adjusted EBITDA. The company is commercializing its Nulexa molecular platform...

    Benzinga•10/13/26•Bearish

    Law firm probes QuidelOrtho officers for possib...

    Halper Sadeh LLC is investigating QuidelOrtho Corporation's officers and directors for potential breaches of fiduciary duties to shareholders. The law firm offers free consultations and encourages affected long-term...

    Pluang•10/8/26•Bearish

    Did QuidelOrtho Corporation Insiders Breach their Fiduciary Duties to Shareholders?

    Halper Sadeh LLC is investigating whether certain officers and directors of QuidelOrtho Corporation (NASDAQ: QDEL) breached their fiduciary duties to shareholders. Long-term shareholders are encouraged to contact...

    PR Newswire•10/8/26•Bearish

    QDEL Valuation and Fair Value

    P/E
    10.3x
    Forward P/E
    9.6x
    P/FCF
    -4.5x
    PEG
    2.1x
    P/B
    0.5x
    See GNG's fair value

    QDEL Profitability: Margins, ROIC and FCF

    Gross margin
    44.6%
    Operating margin
    -2.1%
    Net margin
    -39.2%
    ROIC
    -17.9%
    ROE
    -45.9%
    FCF margin
    -7.9%
    FCF yield
    -22.2%

    QDEL Competitors

    CompanyTicker
    MannKind CorpMNKD
    Beta Bionics, Inc. Common StockBBNX
    Savara IncSVRA
    Theravance Biopharma IncTBPH
    Ventyx Biosciences IncVTYX
    MoonLake ImmunotherapeuticsMLTX
    Castle Biosciences IncCSTL
    Rigel Pharmaceuticals IncRIGL

    Sector: Healthcare

    QDEL Analyst Ratings

    Consensus
    Hold
    Analysts
    3
    Strong Buy
    0
    Buy
    1
    Hold
    1
    Sell
    0
    Strong Sell
    1

    QDEL Bull Case vs Bear Case

    Bull case

    • QDEL beat EPS estimates in 87.5% of its last 8 reported quarters.

    Bear case

    • QDEL has a -39.2% net profit margin.
    • 33.3% of QDEL's analyst ratings are Sell or Strong Sell.

    QDEL Earnings: Beat Rate and Next Report

    Beat rate
    7 of 8 quarters (87.5%)
    Average surprise
    210.0%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.18
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About QDEL

    Does QDEL pay dividends?

    Quidel Corporation (QDEL) does not currently pay a regular dividend.

    What is QDEL's P/E ratio?

    Quidel Corporation has a price-to-earnings (P/E) ratio of 10.30.

    What is QDEL's market cap?

    Quidel Corporation (QDEL) has a market capitalization of $966.91M with a current stock price of $13.91.

    Related stocks

    Sector: Healthcare

    All stocks starting with Q

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In